<DOC>
	<DOCNO>NCT02790073</DOCNO>
	<brief_summary>To evaluate effect SNF472 top standard care promote wound heal parameter therapeutic response haemodialysis patient calciphylaxis ( calcific uraemic arteriolopathy , CUA ) .</brief_summary>
	<brief_title>Phase 2 Study With SNF472 Calciphylaxis Patients</brief_title>
	<detailed_description />
	<mesh_term>Calciphylaxis</mesh_term>
	<criteria>1 . Patients newly diagnose CUA ( diagnose within 5 week study start ) 2 . Patients sign write informed consent participate clinical trial ( prior clinical trialrelated procedure perform ) , read Patient Information Sheet Informed Consent Form ( ICF ) , opportunity discuss clinical trial Investigator designee 3 . Males female age â‰¥18 4 . Patients maintenance haemodialysis 5 . Patients least minimum level pain VAS scale painkiller strong NSAIDs 6 . Females childbearing potential use highly effective contraceptive measure throughout study AND negative serum pregnancy test entry . Male patient sexual relationship pregnancy occur take adequate contraceptive precaution ( wear condom ) 1 . Body weight 150 kg 2 . BMI &gt; 35 central ( abdominal ) ulcer 3 . History bisphosphonate treatment within 12 month enter study 4 . Severely ill patient without reasonable expectation survival &gt; 6 month accord treat physician 5 . Patients scheduled parathyroidectomy runin study period 6 . Female patient either intend get pregnant undergoing treatment get pregnant , well breastfeed female 7 . Participation another clinical trial experimental drug within 90 day prior inclusion 8 . Any psychological , emotional problem , disorder resultant therapy likely invalidate inform consent , limit ability patient comply Clinical Trial Protocol requirement 9 . Patients , opinion Investigator , consider unsuitable reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Calciphylaxis</keyword>
	<keyword>Calcific Uremic Arteriolopathy</keyword>
	<keyword>Dialysis</keyword>
	<keyword>End Stage Renal Disease</keyword>
	<keyword>Rare disease ( ORPHA280062 )</keyword>
	<keyword>Calcification</keyword>
	<keyword>Calcium Metabolism Disorders</keyword>
	<keyword>Calcinosis</keyword>
	<keyword>Metabolic Diseases</keyword>
</DOC>